BDSX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Biodesix Inc (BDSX) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown revenue growth and improved gross margins, its declining net income and EPS, along with mixed technical indicators and lack of strong trading signals, suggest a cautious approach. Additionally, insider selling and lack of recent positive news or political interest further support a hold recommendation.
The MACD is negatively expanding with a histogram of -0.57, indicating bearish momentum. RSI is at 31.715, which is neutral but close to oversold territory. Moving averages are converging, and the stock is trading near its S1 support level of 14.689, suggesting limited immediate upside potential.
Hedge funds are significantly increasing their positions, with a 1991.20% increase in buying over the last quarter. Analysts have upgraded the stock to Outperform, citing strong revenue guidance and improved balance sheet.
Insiders are selling heavily, with a 531.80% increase in selling activity over the last month. The company reported a significant decline in net income (-51.76% YoY) and EPS (-56.25% YoY). No recent news or political interest to drive sentiment.
In Q4 2025, revenue increased by 40.76% YoY to $28.76M, and gross margin improved to 83.03%. However, net income dropped by 51.76% YoY to -$3.98M, and EPS fell by 56.25% YoY to -0.49.
William Blair upgraded the stock to Outperform, citing strong revenue guidance and execution above targets for three consecutive quarters. However, no specific price target was provided.
